drugset / Trial / NCT04212416

Leflunomide in Treating Patients With Steroid Dependent Chronic Graft Versus Host Disease

NCT04212416

NaSingle-groupOpen-labelTreatment

Summary

This phase I trial studies the side effects of leflunomide in treating patients with steroid dependent chronic graft versus host disease (cGVHD). cGVHD is a common complication of bone marrow transplant. GVHD occurs when immune cells transplanted from a donor (the graft) recognize the transplant recipient (the host) as foreign, and cause damage to the skin, gastrointestinal tract or other organs. Steroids are the first line of therapy and benefits are seen in about one-third of patients with cGVHD. Prolonged use of steroids is associated with multiple complications. Leflunomide may decrease the body's immune response and reduce inflammation associated with cGVHD.

Timeline

Start
2020-05-12
Primary completion
2027-06-17
Completion
2027-06-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Leflunomide Small molecule Oral